Albutrepenonacog alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Albutrepenonacog alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
8
Registered trials
11
Result records
34
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Albutrepenonacog alfa can convert its Recombinant coagulation factor, HSA fusion protein profile and F10 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Albutrepenonacog alfa (query alias: albutrepenonacog alfa) |
|---|---|
| Modality / target | Recombinant coagulation factor, HSA fusion protein; F10; F10 stimulants, Blood coagulation pathway activation |
| Highest global status | Approved |
| Originator | CSL Behring LLC |
| Active developers | CSL Behring LLC, CSL Behring GmbH, CSL Behring Lengnau AG |
The MCP disease footprint includes Hemophilia B, Hemorrhage. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04108260 | Phase 4 | Unknown status | 5 | AsBR |
| NCT02053792 | Phase 3 | Completed | 97 | Total Number of Participants Who Developed Inhibitors Against Factor IX (FIX) |
| NCT06399289 | Phase 3 | Active, not recruiting | 23 | Incremental recovery (IR) (plasma FIX activity) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Retrospective Study of the Effectiveness and Safety of the Use of rIX-FP in Patients with Haemophilia B. Experience of four centres in the Region of Castilla y León.
Not Applicable; n=8; evaluation: Positive. Reported fields: ABR = 72.41 %
A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Phase 3; n=97; evaluation: not stated. Reported fields: -; -; -
Real world experience using rIX-FP prophylaxis in patients with haemophilia B: experience from a Spanish centre.
Not Applicable; n=5; evaluation: not stated. Reported fields: Infusion frequency = 7 days
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Albutrepenonacog alfa addresses Hemophilia B, Hemorrhage. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant coagulation factor, HSA fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 34 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: F10 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-16 | 上海奥全AUSUSVAR®利伐沙班分散片和美国销售公司签署美国市场销售许可 | Approved | Financial terms not disclosed |
| 2025-11-02 | 贝达药业与晟斯生物达成战略合作 | Phase 3 | Financial terms not disclosed |
| 2025-09-16 | VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment | Phase 1 | US$117.0M upfront; US$2,100.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
